GO:0005365 myo-inositol transmembrane transporter activity

Myo-inositol transmembrane transporter activity (GO:0005365) is a molecular function that mediates the movement of myo-inositol, a cyclohexanehexol, from one side of a membrane to the other. This activity is fundamental for maintaining intracellular myo-inositol concentrations, which are critical for osmoregulation, cell volume control, and the synthesis of inositol phospholipids that participate in signal transduction. Researchers study this term to understand how cells adapt to osmotic stress, how myo-inositol availability influences growth factor signaling, and how defects in transport contribute to disease. The function is carried out by integral membrane proteins that couple myo-inositol movement to ion gradients or facilitate diffusion, and its annotation is supported by biochemical and genetic evidence. Because myo-inositol is a growth factor for animals and microorganisms, its transport is tightly linked to nutrient sensing and metabolic homeostasis. This article provides a research-grade overview of GO:0005365, covering its definition, mechanism, key genes, disease relevance, and experimental strategies for functional studies.

In our own words, GO:0005365 myo-inositol transmembrane transporter activity refers to the ability of a protein to facilitate the passage of myo-inositol across a biological membrane. This transfer can occur via facilitated diffusion or secondary active transport, depending on the specific transporter. The activity is defined by its substrate (myo-inositol) and its directionality across a membrane, and it is distinct from enzymes that metabolize myo-inositol or receptors that bind it. The synonym vitamin Bh transporter activity reflects the historical recognition of myo-inositol as a vitamin-like growth factor.

GO:0005365 is important because myo-inositol is not only a compatible osmolyte but also the precursor for phosphoinositides, which are central to calcium signaling, membrane trafficking, and cell growth. Transporters with this activity determine the intracellular availability of myo-inositol, thereby influencing the entire inositol lipid cycle. In microorganisms and animals, myo-inositol serves as a growth factor, and its uptake is essential for survival under hyperosmotic conditions. Consequently, understanding this molecular function provides insights into basic cell physiology and offers potential therapeutic targets for diseases characterized by inositol imbalance or altered signaling.

The following genes encode proteins with myo-inositol transmembrane transporter activity or are closely associated with its function.

The activity of myo-inositol transporters is regulated at multiple levels. Transcriptional regulation by osmotic stress via TonEBP/NFAT5 increases SLC5A3 expression, leading to enhanced myo-inositol uptake. Post-translational modifications, such as phosphorylation, can modulate transporter trafficking and activity. Additionally, the availability of sodium gradients and the activity of other ion channels influence secondary active transport. Hormones such as insulin and vasopressin can also affect myo-inositol transport in specific tissues.

Altered myo-inositol transport and metabolism have been implicated in diabetic neuropathy and nephropathy. Hyperglycemia can lead to intracellular myo-inositol depletion, affecting phosphoinositide signaling and contributing to nerve dysfunction.

Myo-inositol serves as an osmolyte and signaling precursor in the brain. Dysregulation of its transport has been associated with mood disorders, Alzheimer's disease, and Down syndrome, where SLC5A3 is overexpressed due to trisomy 21.

Myo-inositol and its derivatives are involved in cell growth and survival pathways. Transporters that regulate intracellular myo-inositol levels may influence tumor progression and response to therapy, making them potential targets for cancer research.

Defects in myo-inositol transport can impair cell volume regulation, leading to cellular damage in tissues exposed to osmotic stress, such as the kidney medulla and lens of the eye.

Radiolabeled myo-inositol uptake assays are the gold standard for measuring transporter activity. Cells expressing the transporter of interest are incubated with [3H]-myo-inositol, and uptake is quantified by scintillation counting. This method allows determination of kinetic parameters such as Km and Vmax.

For electrogenic transporters, patch-clamp or two-electrode voltage clamp in Xenopus oocytes can measure substrate-induced currents. This technique provides real-time information on transport stoichiometry and voltage dependence.

Fluorescent myo-inositol analogs or genetically encoded sensors can be used to monitor transport in live cells. These assays enable high-throughput screening for modulators of transporter activity.

Genome-wide CRISPR knockout or activation screens can identify genes that regulate myo-inositol transport or that are essential for cell growth under osmotic stress. Such screens often use viability or reporter-based readouts.

Researchers studying myo-inositol transmembrane transporter activity-related genes often need to determine whether a candidate gene is causally involved in transport, how mutations affect function, and what downstream pathways are impacted. EDITGENE provides a comprehensive suite of CRISPR-based services to address these questions with precision and reproducibility.

GO:0005365 myo-inositol transmembrane transporter activity is a fundamental molecular function that governs the cellular uptake and distribution of myo-inositol, a critical osmolyte and signaling precursor. Its dysregulation has been implicated in a range of diseases, from diabetic complications to neurological disorders. Advances in CRISPR-based genetic models and functional assays are enabling researchers to dissect the mechanisms and regulation of these transporters with unprecedented precision. EDITGENE stands ready to support these efforts with tailored cell models and screening services.